With over 30 million people in India suffering from chronic obstructive pulmonary disease (COPD) and asthma, there is a critical unmet need to look at new gen technologies to manage the chronic disease conditions and improve the quality of life of patients. 

Ahmedabad-based startup TatvaCare, which specialises in cutting-edge technological advancements in healthcare, has created a novel, digital therapeutics (DTx) platform MyTatva which aims to bridge this need.

TatvaCare will be commencing clinical trials to test the application at various centres across India. More than 150-200 subjects will be randomly tested to gauge the user efficacy and advantages.

Based on the outcomes of the trial, TatvaCare will launch this first-of-its-kind digital therapeutics solution in India for COPD and Asthma management. The market for digital health applications in India is valued at $3.8 billion, estimated to jump to $18 billion by 2030 with TatvaCare being one of the early entrants in this highly specialised domain.

A panel of distinguished pulmonologists from across India will be overseeing the study under the leadership of Dr Agam Vora, a renowned pulmonologist from Mumbai. Named as BREATHE DTx, the study will be conducted across 8 centres in India. 

Spanning 6 months, the Randomised Controlled Trial (RCT) will provide a comprehensive assessment of MyTatva's effectiveness from the real-world evidence gathered.